GTC Presents at the 2019 ASCO Annual Meeting
Genomic Testing Cooperative (GTC) and Collaborators to Present data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019
Genomic Testing Cooperative (GTC) and Collaborators to Present data Resulting from its Proprietary DNA and RNA Profiling of Diffuse Large B-cell Lymphoma at the 2019
Recent study published in Nature Medicine (Rodon et al, Nature Medicine volume 25, pages 751–758, 2019) showed that molecular profiling using both DNA and RNA
CELLGEN DIAGNOSTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO ESTABLISH A NEW STANDARD IN CO-DEVELOPMENT OF COMPANION DIAGNOSTICS FOR CANCER THERAPIES Alliance will enable a faster
23rd Annual International Congress on Hematologic Malignancies 2019: Focus on Leukemias, Lymphomas and Myeloma The annual International Congress on Hematologic Malignancies is dedicated to
A quick interview from Genomic Testing Cooperative founder, CEO/CMO, Dr. Albitar, introducing Genomic Testing Cooperative answering questions about it… Get all the answers by watching
Time Matters on Health Tests When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible. Are
-a step forward to precision in cancer diagnostics- CSI LABORATORIES ADVANCES BY PARTNERING WITH DR. MAHER ALBITAR OF GENOMICS TESTING COOPERATIVE (GTC) Membership in the Co-Op also
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts The vast majority of
Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk
Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations. Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers